Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2025 · 10-Q
Revenue$393.07K$393.07Kderived−60.0% vs Q3 2024 Net Income-$9.89M-$9.89MN/M vs Q3 2024 EPS Diluted-$4.51-$4.51N/M vs Q3 2024 Gross Profitderived-$23,841N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Income-$9,544,679N/M Operating Cash Flowderived-$2,469,628N/M Margins · derivedGross margin-6.1%−35.7 pt vs Q3 2024
Operating margin-2428.2%−2156.3 pt vs Q3 2024
Net margin-2515.1%−2034.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 19, 2025 · 50 d after period end